HTG Molecular Diagnostics (NASDAQ:HTGM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
Several other equities analysts have also recently weighed in on HTGM. ValuEngine cut HTG Molecular Diagnostics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 10th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of HTG Molecular Diagnostics in a research report on Wednesday, November 8th. Finally, Canaccord Genuity boosted their price objective on HTG Molecular Diagnostics to $5.00 in a research report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $5.25.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings data on Tuesday, November 7th. The medical research company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.03. equities analysts anticipate that HTG Molecular Diagnostics will post -1.92 EPS for the current year.
An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Vanguard Group Inc. raised its position in HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 135,234 shares of the medical research company’s stock after acquiring an additional 37,841 shares during the period. Vanguard Group Inc. owned about 1.42% of HTG Molecular Diagnostics worth $359,000 as of its most recent SEC filing. 15.15% of the stock is owned by hedge funds and other institutional investors.
WARNING: “HTG Molecular Diagnostics (HTGM) Lowered to Hold at Zacks Investment Research” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2018/01/20/htg-molecular-diagnostics-htgm-lowered-to-hold-at-zacks-investment-research.html.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.